SEC FORM 3

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Clark George C.

(Last)

(First)

(Middle)

C/O BIOHAVEN PHARMACEUTICALS, INC.

215 CHURCH STREET

(Street)

NEW HAVEN

06510

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
08/06/2021

3. Issuer Name and Ticker or Trading Symbol
Biohaven Pharmaceutical Holding Co Ltd. [ BHVN ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	VP, Chief Accounting Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Shares	5,558⁽¹⁾	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Employee Stock Option (right to buy)	⁽²⁾	05/06/2031	Common Shares	10,000	$71.44	D
Employee Stock Option (right to buy)	⁽³⁾	01/06/2031	Common Shares	7,000	$83.38	D
Employee Stock Option (right to buy)	⁽⁴⁾	12/05/2029	Common Shares	8,250	$53.76	D
Employee Stock Option (right to buy)	⁽⁵⁾	11/20/2028	Common Shares	6,710	$32.42	D
Employee Stock Option (right to buy)	⁽⁶⁾	03/11/2028	Common Shares	1,250	$30.32	D
Restricted Share Unit Award	⁽⁸⁾	⁽⁹⁾	Common Shares	20,000	⁽⁷⁾	D
Restricted Share Unit Award	⁽¹⁰⁾	⁽⁹⁾	Common Shares	2,625	⁽⁷⁾	D
Restricted Share Unit Award	⁽¹¹⁾	⁽⁹⁾	Common Shares	2,000	⁽⁷⁾	D

Explanation of Responses:

1. This balance includes 700 shares and 288 shares that were acquired through the Biohaven Employee Share Purchase Plan on November 30, 2020 and May 31, 2021, respectively, and 200 shares held in an individual retirement account.

2. The shares underlying this option became exercisable as to 2,500 of these shares on May 7, 2021, with the remainder vesting in 3 equal installments on May 7, 2022, 2023, and 2024, subject to the reporting person's continuing service as of each applicable vesting date.

3. The shares underlying this option became exercisable as to 1,750 of these shares on January 6, 2021, with the remainder vesting in 3 equal installments on January 6, 2022, 2023, and 2024, subject to the reporting person's continuing service as of each applicable vesting date.

4. The shares underlying this option became exercisable as to 3,750 of these shares on and prior to December 5, 2020, with the remainder vesting in 2 equal installments on December 5, 2021, and 2022, subject to the reporting person's continuing service as of each applicable vesting date.

5. The shares underlying this option became exercisable as to 960 of these shares on and prior to November 20, 2020, with the remainder vesting in 2 equal installments on November 20, 2021, and 2022, subject to the reporting person's continuing service as of each applicable vesting date.

6. The shares underlying this option will vest on March 12, 2022, subject to the reporting person's continuing service as of each applicable vesting date.

7. Each restricted share unit represents the contingent right to receive one common share of the Issuer.

8. The reporting person was granted 20,000 restricted share units on May 7, 2021, vesting in four equal installments on May 7, 2021, 2022, 2023 and 2024, subject to the reporting person's continued service with the Issuer at each vesting date.

9. Not applicable.

10. The reporting person was granted 3,500 restricted share units on January 6, 2021, vesting in four equal installments on January 6, 2021, 2022, 2023 and 2024, subject to the reporting person's continued service with the Issuer at each vesting date.

11. The reporting person was granted 4,000 restricted share units on January 8, 2020, vesting in four equal installments on January 8, 2020, 2021, 2022 and 2023, subject to the reporting person's continued service with the Issuer at each vesting date.

Remarks:

Exhibit List: Exhibit 24: Power of attorney

	/s/ George C. Clark	08/13/2021
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.